A phase I, open label, multi-center,dose escalation clinical study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of CN1 in patients with advanced solid tumors or B-cell lymphoma

  • Park, John (Primary Chief Investigator)
  • Chapman, Nicola, (Clinical Trial Unit Staff)
  • Gurney, Howard (Associate Investigator)
  • Sabanathan, Dhanusha, (Associate Investigator)

Project: Research

Project Details

AcronymCN1-101
StatusActive
Effective start/end date3/08/2030/06/25